Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Randomized, Open-label, Multicenter Study to Determine the Safety and Efficacy of different MONoclonal Antibodies (MoAbs) to SARS-CoV-2 for the Early Treatment of COVID-19 in Non-hospitalized Adults

Next Previous
Search
Trial Profile

A Phase III Randomized, Open-label, Multicenter Study to Determine the Safety and Efficacy of different MONoclonal Antibodies (MoAbs) to SARS-CoV-2 for the Early Treatment of COVID-19 in Non-hospitalized Adults

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Casirivimab (Primary) ; Casirivimab/imdevimab (Primary) ; Cilgavimab/tixagevimab (Primary) ; Imdevimab (Primary) ; Nirmatrelvir+ritonavir (Primary) ; Sotrovimab (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Acronyms Monet

    • Most Recent Events

    • 22 Feb 2023 Interim Results (n=400)presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023
    • 22 Feb 2023 Results of post hoc analysis (n=320; between 4 Mar and 16 Nov, 2022) assessing the impact of SARS-Cov-2 variants on the decline of viral load after treatment with 3 different drugs approved in EU for the early treatment of patients with mild-moderate COVID-19, presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023.
    • 08 Mar 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top